Felice Verduyn-van Weegen has been a member of the board of directors of Evommune since September 2021 and is a Partner at EQT. Felice worked for LSP from 2015 until 2022, when LSP joined forces with EQT and became EQT Life Sciences. Prior to joining LSP, Felice worked as a Consultant at McKinsey & Company in Amsterdam. Prior to working at McKinsey, Felice was a Neuroscientist and Statistical Geneticist, working with the prestigious Complex-Traits Genetics Group at the Broad Institute and Harvard Medical School in Cambridge, Massachusetts. Felice holds an M.S. (cum laude) in neuroscience from Vrije Universiteit Amsterdam and an M.B.A. (with distinction) from Columbia Business School in New York.
6 of 8